<SEC-DOCUMENT>0001213900-14-007787.txt : 20141106
<SEC-HEADER>0001213900-14-007787.hdr.sgml : 20141106
<ACCEPTANCE-DATETIME>20141106070555
ACCESSION NUMBER:		0001213900-14-007787
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20141106
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20141106
DATE AS OF CHANGE:		20141106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		141198754

	BUSINESS ADDRESS:	
		STREET 1:		546 5TH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		212-300-2131

	MAIL ADDRESS:	
		STREET 1:		546 5TH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k110614_actiniumpharma.htm
<DESCRIPTION>ACTINIUM PHARMACEUTICALS, INC. FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<HR SIZE="4" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">

<HR SIZE="1" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report (Date of earliest event reported):
November 6, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ACTINIUM PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its
charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 30%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Delaware</b></font></td>
    <td style="width: 3%; padding-bottom: 1.5pt">&nbsp;</td>
    <td style="width: 30%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>000-52446</b></font></td>
    <td style="width: 3%; padding-bottom: 1.5pt">&nbsp;</td>
    <td style="width: 34%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>88-0378336</b></font></td></tr>
<tr style="vertical-align: top">
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(State or other jurisdiction</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">of&nbsp;incorporation)</P></td>
    <td>&nbsp;</td>
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Commission</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">File Number)</P></td>
    <td>&nbsp;</td>
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Identification No.)</P></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr>
    <td style="vertical-align: bottom; width: 68%; border-bottom: black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>501 Fifth Avenue, 3rd Floor</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>New York, NY</b></P></td>
    <td style="vertical-align: top; width: 2%; padding-bottom: 1.5pt">&nbsp;</td>
    <td style="vertical-align: bottom; width: 30%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>10017</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt">(Address of principal executive offices)</font></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><font style="font-size: 10pt">(Zip Code)</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(646) 459-4201</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 100%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>N/A</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt">(Former name or former address, if changed since last report)</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<U>see</U> General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 6%; text-align: center"><font style="font: 10pt Wingdings">o</font></td>
    <td style="width: 94%"><font style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 6%; text-align: center"><font style="font: 10pt Wingdings">o</font></td>
    <td style="width: 94%"><font style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 6%; text-align: center"><font style="font: 10pt Wingdings">o</font></td>
    <td style="width: 94%"><font style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 6%; text-align: center"><font style="font: 10pt Wingdings">o</font></td>
    <td style="width: 94%"><font style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>








<HR SIZE="1" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">

<HR SIZE="4" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 7.01. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulation FD
Disclosure. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 6, 2014, Actinium Pharmaceuticals,
Inc. (the &ldquo;Company&rdquo;) issued a press release announcing positive interim data from the ongoing Phase I/II trial of Actimab-A
in older patients with newly diagnosed Acute Myeloid Leukemia. A copy of the Company&rsquo;s press release is attached as Exhibit
99.1 to this Current Report on Form 8-K and is incorporated into this Item&nbsp;7.01 by reference. In accordance with General Instruction
B.2 of Form 8-K, the information set forth herein is deemed to be &quot;furnished&quot; and shall not be deemed to be &quot;filed&quot;
for purposes of the Securities Exchange Act of 1934, as amended. The information set forth in Item 7.01 of this Current Report
on Form 8-K shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is
required to be disclosed solely to satisfy the requirements of Regulation FD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial
Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(d) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt">Exhibit No.</font></td>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</td>
    <TD STYLE="width: 90%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt">Description</font></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><font style="font-size: 10pt">99.1</font></td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">Actinium Pharmaceuticals, Inc., press release dated November 6, 2014.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr>
    <td style="width: 100%">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Dated: November 6, 2014</font></td>
    <td colspan="2"><font style="font-size: 10pt"><b>ACTINIUM PHARMACEUTICALS, INC.</b></font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; width: 55%">&nbsp;</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 33%">&nbsp;</td>
    <td style="width: 10%">&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top; padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="vertical-align: top; padding-bottom: 1pt"><font style="font-size: 10pt">By:</font></td>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid"><font style="font-size: 10pt"><i>/s/ Kaushik J. Dave&nbsp;</i></font></td>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <TD COLSPAN="2" STYLE="vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name:&nbsp;&nbsp;Kaushik J. Dave</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Title:&nbsp;&nbsp; President and Chief Executive Officer</P>

</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">2</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<HR NOSHADE SIZE="1" STYLE="color: Black; width: 100%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>f8k110614ex99i_actiniumphar.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="color: Red; font: 10pt/107% Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black"><B><A NAME="ex991"></A>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt/19.45pt Times New Roman, Times, Serif; margin: 0 0.9pt 0 0; text-align: center"><FONT STYLE="color: #424241"><B>&nbsp;</B><IMG SRC="logo.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt/19.45pt Times New Roman, Times, Serif; margin: 0 0.9pt 0 0; text-align: center"><FONT STYLE="color: #424241"><B>Actinium<FONT STYLE="letter-spacing: -0.4pt">
</FONT>Pharmaceuticals,<FONT STYLE="letter-spacing: 1.1pt"> </FONT>I<FONT STYLE="letter-spacing: -0.2pt">n</FONT></B></FONT><B><FONT STYLE="color: #2A2828; letter-spacing: 0.2pt">c</FONT><FONT STYLE="color: #424241">.</FONT></B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><B>Actinium Pharmaceuticals
Actimab-A Phase I/II Trial Interim Data Demonstrate Extension of Overall Survival to 9.1 months in Elderly Secondary Acute Myeloid
Leukemia</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Significant Reductions in Bone Marrow Blasts Demonstrated</I></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>No Early Mortality Observed</I></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>ASH Abstract Highlights Actimab-A&rsquo;s Significant Survival Benefit in Patients with Secondary Acute Myeloid Leukemia</I></TD></TR></TABLE>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><B>New York, NY</B> &ndash; November
6, 2014 -- Actinium Pharmaceuticals, Inc. (&ldquo;Actinium&rdquo; or the &ldquo;Company&rdquo;) (NYSE MKT: ATNM), a biopharmaceutical
company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced positive
interim data from the ongoing Phase I/II trial of Actimab-A in older patients with newly diagnosed Acute Myeloid Leukemia (&ldquo;AML&rdquo;).
Most notably, median overall survival (&ldquo;OS&rdquo;) of the seven secondary AML patients (with prior myelodysplastic syndrome,
or MDS) in the study was 9.1 months, which is a prolongation of life compared to historical norms of typically 2 to 5 months.<SUP>1
</SUP>Older AML patients are already higher risk, with secondary AML patients considered to have the more severe and less treatable
form of AML, and the shortest expected survival. The clinical abstract will be published and available online in <I>Blood</I>,
the official Journal of the American Society of Hematology.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&ldquo;Alpha emitting isotopes may
result in more efficient leukemia cell killing without the toxicity of intensive chemotherapy,&rdquo; said Joseph Jurcic, M.D.,
Professor of Medicine and Director of the Hematologic Malignancies Section of the Hematology/Oncology Division at Columbia University
Medical Center, and lead study investigator. &ldquo;In this study, Actimab-A was safely and effectively combined with low-dose
chemotherapy in older AML patients. Even at this early stage in development, the tolerability of the regimen and promising survival
data in this poor-risk population are highly encouraging and support our center&rsquo;s commitment to this program. Because many
of these patients cannot tolerate intensive chemotherapy, potentially less toxic treatments such as this are desperately needed.&rdquo;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&quot;We believe the data presented
provide further evidence that Actimab-A has substantial clinical activity, including a survival benefit, in the hardest to treat
AML patients,&quot; said Dragan Cicic MD, Chief Medical Officer of Actinium. &quot;The potential efficacy in killing other treatment
resistant leukemia cells combined with the limited side effects identified in the study to date could offer a new hope to patients
whose age, comorbidities and nature of disease currently leaves them with very limited treatment options. We continue to work with
a world-class team of clinical investigators to advance this program and technology.&quot;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">&nbsp;</P>

<HR ALIGN="LEFT" SIZE="1" STYLE="width: 33%">

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><SUP>1</SUP> <I>Oran B, and Weisdorf DJ. Survival
for older patients with acute myeloid leukemia: a population-based study. Haematologica 2012; 97(12):1916-1924. doi:10.3324/haematol.2012.066100.</I></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><I><SUP>1 </SUP>N Okuyama et al, Prognosis of acute
myeloid leukemia transformed from myelodysplastic syndromes: A multicenter retrospective study, Leukemia Research 37 (2013)
862&ndash; 867</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The interim analysis from this company-sponsored
trial is consistent with results from the prior three trials in Actinium&rsquo;s HuM195-Alpha Program. The abstract, <I>Phase I
Trial of Targeted Alpha-Particle Therapy Using Actinium-225 (<SUP>225</SUP>Ac)-Lintuzumab (Anti-CD33) in Combination with Low-Dose
Cytarabine (LDAC) for Older Patients with Untreated Acute Myeloid Leukemia (AML)</I>, will be published and available online in
<I>Blood</I>, the official Journal of the American Society of Hematology.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">In this interim analysis, a total
of 9 patients were evaluated thus far with a median age of 76 (range 73-81). All had intermediate or poor risk cytogenetics, and
7 of 9 patients had secondary AML as a result of prior MDS. These 7 secondary AML patients had a median OS of 9.1 months from study
entry (range 2.3-24 months). Of these, 2 patients lived longer than 12 months and the longest surviving patient lived greater than
24 months. Overall, for all 9 patients median OS was 5.4 months (range 2.2-24 months).</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Two dosing levels have been evaluated
to date (0.5 or 1.0 &mu;Ci/kg/fraction), and the study is ongoing at higher doses until the maximum tolerated dose (&ldquo;MTD&rdquo;)
is reached. Despite not having yet reached MTD, the Company has observed significant bone marrow blast reductions, another important
marker of efficacy. Of the 7 evaluable patients in the overall study, 5 patients (71%) had bone marrow blast reductions with a
mean of 61% reduction.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The sites participating in this
multi-center trial are Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Johns Hopkins Medicine, Columbia University
Medical Center, University of Pennsylvania Health System, Fred Hutchinson Cancer Research Center, and the Texas Oncology-Baylor
Charles A. Sammons Cancer Center.. The Company expects to announce further information related to Actimab-A development subsequent
to its Clinical Advisory Board meeting, during the ASH 2014 time frame (December 6-9, 2014).</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Elderly, high risk patients ordinarily
have a life expectancy of 5 or fewer months if treated with standard chemotherapy, though only about a third of them do receive
treatment because of toxicity. The other two-thirds receive best supportive care, with 2 months survival, according to Oran and
Weisdorf (<I>Haematologica</I> 2012; 1916-24). The majority (5 of 7) of the secondary AML patients receiving Actimab-A had been
previously treated with hypomethylating agents, a criterion which would have excluded such patients from some other clinical trials.
Previous treatment with hypomethylating agents, and subsequent failure, further demonstrates the disease severity of patients in
the Actimab-A trial.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The safety profile of Actimab-A
was satisfactory and acceptable for this patient population in this interim analysis. The only drug-related serious adverse events
seen were related to myelosuppression, which is expected in the treatment of leukemia.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The antibody portion of Actimab-A,
HuM195 (also known as lintuzumab) when labeled with alpha particles has been evaluated in three prior studies, including two studies
of Bismab-A, which was an earlier, first generation construct, and an investigator sponsored trial with Actimab-A. Today&rsquo;s
interim results mark the first look at what the Company believes are clinically meaningful data in the ongoing, Company sponsored
Phase I/II trial of Actimab-A.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Secondary AML is a common form of
AML in the U.S., and is defined as AML that develops following exposure to cytotoxic agents or as a subsequent event in another
hematologic disorder, usually MDS. According to the American Cancer Society there is an annual incidence of 12,000 new cases of
MDS in the U.S. Between 30% and 50% of these new cases go on to develop AML, or approximately 3,600-6,000 secondary AML patients
in the U.S.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">2</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><B>About Actimab-A</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Actimab-A is a radiolabeled antibody
being developed for newly diagnosed AML in patients over 60, and is currently in a multicenter Phase I/II clinical trial. Based
on Actinium&rsquo;s alpha-particle immunotherapy (APIT) platform, Actimab-A consists of the CD33 antibody lintuzumab linked to
the actinium-225 payload. Actimab-A has attracted support from leading experts at the prestigious and high-volume cancer treatment
hospitals due to the potential of its safety and efficacy profile, as well as its potential potency, specificity and ease of use.
Clinical trials are being conducted at world-class cancer institutions such as Memorial Sloan Kettering Cancer Center, MD Anderson
Cancer Center, Johns Hopkins Medicine, Columbia University Medical Center, University of Pennsylvania Health System, Fred Hutchinson
Cancer Research Center, and the Texas Oncology-Baylor Charles A. Sammons Cancer Center. The Company expects additional updates
to its Phase I/II clinical trial in December 2014. Actimab candidates are in early development for other cancers.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><B>About Actinium Pharmaceuticals</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com)
is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced
cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization
of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies.
The Company's lead radiopharmaceutical Iomab-B will be used, upon approval, in preparing patients for hematopoietic stem cell transplant,
commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study
of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The
Company's second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients
over the age of 60 in a single-arm multicenter trial.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><B>Forward-Looking Statement for
Actinium Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><I>This news release contains &quot;forward-looking
statements&quot; as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's
current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth
in the statements. The forward-looking statements may include statements regarding product development, product potential or financial
performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium
undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events
or otherwise.</I></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>Contact:</B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0">Actinium Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0">Evan Smith, CFA</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0">VP Investor Relations and Finance</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0">(646) 840-5442</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0"><U>esmith@actiniumpharma.com</U></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"></P>



<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">3</P>



<P STYLE="margin: 0"></P>

<HR NOSHADE SIZE="1" STYLE="color: Black; width: 100%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!$`($#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_****`"B
MBC-``3BF&5=F3T'))[5\,_\`!2;_`(+4>'_V/]:O_`W@BQM_&/Q,ME'VF&8N
MFFZ,2`<3.O,DN&4^5'TW`NR\`_DM\<_VY_BY^U%J=WJ'CGX@>);BT:91_9]E
M<M9:3:]=B"WBQ'U'!?>YY!-*X[=S^B^3XN>%(I&1O$OA]74[2IU&$$'T^]UK
M9TW5K76;".ZM)H;JUF&Z.:%UDC<>H8$@BOY=X/@;XCUO2/[3TCP#XIU.TF9B
M;JTT"YFB8C.X^8L)W@#J0W?J*O?#;XT>*_@=J_VOP?XK\3>#[[3W/EIIFI/:
M/""!A&A8%2@(/RNI5CR12Y@T/Z@U(/2AVVK7Y-?\$_O^#A&XDU[3/!WQY^R#
M[?*L%MXPLH1#';LV`JW\"\("2!YR8`S\R*`6K])_VAOVCO"W[,GP;U3QQXKU
M%+;0]-A$@,1#RWCM_JXH5S\[N<!0/KTR:VH4:E:I&C1BY2D[)+5MO9&5:M"C
M3=6J[16K;V2,+]L7]K[PK^Q?\&[OQ=XGD>7YOL^FZ=`1]IU6Z()6&,=NA+,>
M%4$GT/S?_P`$OO\`@JW=?M:^--1\!>/+"'2O'!>XU#2FM(&6UOK,'?Y1'59(
MD(&YL"1<-P<BOS-_:,_:*^(?_!2K]I2*_>UN+Z[U&==*\-^%[24LM@DA)2).
M-A<JN^64X[G(5>,_X@?&.R_9ULCX!^%OB*(>)+:^CE\8>-M.D93JE[`P=;"P
ME&!]@MYP-S#_`(^)$R?W:J#^OY[PEE'#G#WLLT]_'5K.*3^"WZ=W]IZ+:Y^7
MY/Q)FF>9XI9=[N$I:2;7Q7_7MV6KWL?T51')XJ2OD7_@D3_P43OOV^O@I>G7
M](GL/&/@\PV>LWD$!73=3=U)2:%NBR%5S)%_`6&/E85]<KTK\;6Q^J;:"T44
M4P"BBB@`I&;%+3';#B@#QW7O^"AGP/\`"^MWNFZC\4_!%I?Z;.UK=6\FJ1B2
MWE5BK(PSP0P(/H17@_\`P4&_X*X>"/AM^S'KDWPG\;>%?%'C[4U^P:6EI?I*
M-.,@.^\<`](D!*C^*0HN#DU\0_M`_P#!(#XM>./CMXWUFUU?X9)8ZMXAO[^U
MBG\4I&ZQRW4D@#H4^5L,<C/!S7S%^TW^REXE_9(\<Z9HWBN_\/W%SJ5F=0BE
MT74OMUN$#E<,X4;&ROW?H<U^ZX3P^X1J4H3GF=FTFU[NC:U6Q^1XGC7B2G4E
M&&7W2;2>NOF<'H_A+7?'WB^TBN-7TZ#4-7GQ-J.JZF$MA-(_[R:YF)+*#]]G
M()SVS@5^N/[#7PX_8W_8Y\+Z==:C\1_A[XW\?L!->>(-2G6;$Q'(M82"L*#&
M`0-_&6;/3\X?V6OV)?%_[8::K)X:U'PM"GA\P)<2ZWJAT_SA('V^673]YL"$
M';T)&>M>M#_@C)\7\,6\2?"8L2"67Q:G'3U3MQBM9>'G!J?_`"-'_P"2_P"1
M@N-^)VK_`-GW_P#`C]:I/^"GW[/MO;1NWQ<\&B)P=I%YUP<'H*X?Q_9_LL?\
M%39+CPJ=4\(>,_$4-G+-;WFEOY6KZ;&,(TT,X4,-I=>#E3D94BOS.U'_`((T
M?%&W1$'B7X1,B@!3)XPC7GJ2/W73<2:^GO\`@C__`,$^?''[,?[7%UXD\2:S
M\/+ZR;P]=60AT7Q`M]<AY)86!,813MPIRWJ17CY[P7PMA,NJXG!Y@ZE6*]V.
MFK^X]3)^+.(,3C:=#%8+DIR=G+71'Y\_\%!?V`?%G[`7Q>E\-ZTLFK^'=366
M;PUX@CAVQZK#W27'RI<)NPZ'MAE.TUZE^R3\?K+]KGX+VO[.'Q<\0&U72Y#<
M_#CQ9?SB.'0-02)T73[MV($ULX+(C$%DW!/[A'[7_M6?LM>$?VP_@MJ?@?QE
M8_:=-OQYD,\9V7.FW"@^7<0OU61"3CL02IR"0?YU?VK_`-FW6/V4OCUXA\`^
M(;JVU6]\/RB-+_3WWVUQ&P#Q/C/R2;67?&V2K<8/!K\EP..KX/$0Q>%ERS@T
MTUW/T?%X2EB:$L/75X25FO)GJWQ&\0Z;^R%X9U+X=>']>TO5OBSK1?3_`!MK
M^FNTUKH-J5(DT>QG`'[UL!;B=0"03$IP'SR7[#O[$?B7]O/XU0>#?"MLNEZ%
M`BS>(-:6-FCT6V8XP=P7?*VPB-/XFY)VJU<#^S]\"]3_`&C_`(Q^%_`FB7NG
M:7J/B>]%K;7.I2?9H`Q+,23U8[=YV`DLVU1R17]&/[&/['OA/]B/X(6'@OPN
MDLRHQN=2U*YYNM7NV`$EQ*?4XP%'"J`HX%=&;9QB\TQ<L;CI<TY?AV271+HD
M899E>&R[#1PF$CRPC_5WYG2?L\?L]^%_V7OA)HW@OPAIZ:?HNC0B-!@>;<.?
MOS2L`-\KGYF8]2?3`KMZ**\\[PHHHH`****`"FL<,*=2$9H`_!+]I/\`X)=_
M'[QI^T?X_P!9TWX4>(+W3]6\2ZE=VER);0I-#)=2O&ZAILX96!Y`Z]!7D_QA
M_80^+W[/7@FX\2>-?!&H>$?#]LZ0_;-1O+**-G?A4`64LSGG"J"?RR/Z1=@]
M!^5>6_ME?LH^'_VTOV>?$/P^\1+Y=OK%N?LEZB!IM+NEYAN8\_Q(^#VR,CH3
M7[5AO'+.:%*%*-"E:*2VGT5OYS\LK^$N5U:DJLJM2\FWO'K_`-NG\Y/@?P'J
M/Q&\3:5X9TD6^J:SJ<RV]C:-?6X,\S_=BB+N$#,>V022..:]J7_@DY^T-&__
M`"1KQ*%0;5Q-9DL.1_SVP,?CUKQ3]I_]F3Q7^Q_\6;[P)XUTK[!KEH_F07,3
MLL%]`IQ'>6SD#=&VT'Y3N1EP=I%??G["W_!PIK7P\T"W\,?&70M2\5V^G011
M6WB'1E634`@4`+<Q$JLK8&?,#*QYRI;)K5^/.=-_P*7W3_\`DR%X0Y5_S^J?
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M2^+?%=QA'E)D:[9V+3W5Q,<E%7!D=R2`,="0*LZ@_B?]I7XNR7#QZQXR\;>-
M+]9&\H>=>:O=3-@JN`-H&U=H(V(HYPHQ7Z3^,_\`@EE\0?V"/^"<NO7GPYFM
M;_XF>(H@WC[4;-&;48])'S-8Z:R_=C3@RD8:4*Q&/E4?F>5X#Z[C:6$<U#G:
M7-+1*_5GWF88Q87"U,0HN7*F[+=V/S7^//P7U7]G+XI7OAWQ%=QK=VD<-Y:7
M6E71EM-0M^62\L[B,C?&Q#;6&")!M(5E./UY_P""+W_!6]?VE-(LOA7\2M41
MOB1IT!_LK5II$"^*K=!DY(X^UQKC>O5P-XYW8_+WX:^+O#7Q&^&T7PT\?7"6
M/AC[0]UX:\2-$93X.OW8;G^7YFTZ8\SPC[I(E0;@0W`>+/A3XF^"/Q5N=%OT
M;P[XH\,7"W4=U:7`C%M*N)8KJVN5*AHW&R2.9#\RL"!U%>_QIP=C.'L<\-7]
MZ$KN$[:27_R2ZJ_GLSQN%^*,-G>%]O1TFOBCU3_R[']2P.:6OCG_`((Z_P#!
M0[4OVY_@S>6/B;3;J+QCX(2"TU74XEWZ?K(=3Y=PCJ`JS,$/F1?PGYA\K#'V
M-7R>Y](%%%%`!1110`4444`%(1FEHH`\M_:O_8U^'?[:7P[/ASX@Z!!JUM$6
M>SNT/DWVF2,,&2WG'SQL1C.#A@,$$5^7?QP_X-L/'7@N^O)OA;X\TG7M%W&2
M'3M:#V&I;,?ZHS1@P2GC`+)&.>:_9:B@#^?%O^"*W[36F:O]AD^%JSF238ES
M:^(++[+'DY#DF4'Z\?A7I/PA_P"#>/X[>-KYO^$LU3P;X*LD?#-)=-J4\HQP
M5CAPO?H9%''W3UK]Q:*0'S/^PC_P2O\`AG^PC"=1T2WGU_QG<0?9[KQ)J0#7
M3(<;HX4'RP1G`R$Y/\3-@5]*/"`O7&*DH/(I@?CY_P`%E_\`@E:/A/J-_P#%
MWX<:7_Q2UU,USXFTBV@W'1Y'8LUY"HY\AF.9%'W#\P^4G;\]?L6_!'4?^"A5
MUI'PCNX+\W7AJ/[9I'BV&W2Z_P"$;L-^Z>QN@SKYMG*3^Y4'?%,<J"C.!_0!
M>Z=%J-K)!/''-!.C1RQR(&216&"K`\$$9!%>??LX?LE^`_V2_#&HZ1X!T&VT
M&RU6_EU&Z$>7>65V)P68EMB`[43.$48%?IS\0UBN&YY)FE+VM2-O9S;^'S?6
M\>G=:/S_`#]<$O#Y[#-<OJ>S@[\\>_DO)]>W0F_9A_9H\(?LD?!_2O`_@K3(
M],T;2TR3UFO9F_UEQ,_5Y7/))^@P``/0^E-1-G?-.K\Q1^@!1110`4444`%%
E%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`?_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
